Initial evaluation of the Parent Cystic Fibrosis Questionnaire-Revised (CFQ-R) in infants and young children

Adrianne N. Alpern, Lyndia C. Brumback, Felix Ratjen, Margaret Rosenfeld, Stephanie D. Davis, Alexandra L. Quittner

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: There is an urgent need to evaluate treatments for young children with cystic fibrosis (CF); however, efforts have been hampered by a lack of reliable, practical endpoints. To examine whether a patient-reported outcome could be reliable in children 4 to 60. months of age, we assessed the psychometric properties of the modified Parent Cystic Fibrosis Questionnaire-Revised (CFQ-R) using data from the Infant Study of Inhaled Saline (ISIS). We also characterized patterns of symptom presentation and daily functioning in children in this age range to inform future measure development. Methods: Parents ( N = 314) completed the CFQ-R and Treatment Adherence Questionnaire (TAQ) at five quarterly visits, as well as a weekly Parent Symptom Diary. Results: The Parent CFQ-R demonstrated good construct validity and adequate internal consistency (α's 58 - 75). Associations with age, TAQ, and Parent Symptom Diary were observed. The Treatment Burden scale demonstrated responsiveness to change. Conclusions: Parents were reliable observers of young children's symptoms and daily functioning, and PROs show promise for this age group. Research is needed to identify key symptoms in infants and young children with CF, and to develop a parent proxy PRO according to FDA/EMA guidelines.

Original languageEnglish (US)
Pages (from-to)403-411
Number of pages9
JournalJournal of Cystic Fibrosis
Volume14
Issue number3
DOIs
StatePublished - May 1 2015

Fingerprint

Cystic Fibrosis
Parents
Proxy
Therapeutics
Psychometrics
Age Groups
Surveys and Questionnaires
Guidelines
Research

Keywords

  • Health-related quality of life
  • Infants
  • Patient reported outome
  • Psychometric evaluation
  • Treatment burden

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Initial evaluation of the Parent Cystic Fibrosis Questionnaire-Revised (CFQ-R) in infants and young children. / Alpern, Adrianne N.; Brumback, Lyndia C.; Ratjen, Felix; Rosenfeld, Margaret; Davis, Stephanie D.; Quittner, Alexandra L.

In: Journal of Cystic Fibrosis, Vol. 14, No. 3, 01.05.2015, p. 403-411.

Research output: Contribution to journalArticle

Alpern, Adrianne N. ; Brumback, Lyndia C. ; Ratjen, Felix ; Rosenfeld, Margaret ; Davis, Stephanie D. ; Quittner, Alexandra L. / Initial evaluation of the Parent Cystic Fibrosis Questionnaire-Revised (CFQ-R) in infants and young children. In: Journal of Cystic Fibrosis. 2015 ; Vol. 14, No. 3. pp. 403-411.
@article{95a225a9a98549838983665c7605b12b,
title = "Initial evaluation of the Parent Cystic Fibrosis Questionnaire-Revised (CFQ-R) in infants and young children",
abstract = "Background: There is an urgent need to evaluate treatments for young children with cystic fibrosis (CF); however, efforts have been hampered by a lack of reliable, practical endpoints. To examine whether a patient-reported outcome could be reliable in children 4 to 60. months of age, we assessed the psychometric properties of the modified Parent Cystic Fibrosis Questionnaire-Revised (CFQ-R) using data from the Infant Study of Inhaled Saline (ISIS). We also characterized patterns of symptom presentation and daily functioning in children in this age range to inform future measure development. Methods: Parents ( N = 314) completed the CFQ-R and Treatment Adherence Questionnaire (TAQ) at five quarterly visits, as well as a weekly Parent Symptom Diary. Results: The Parent CFQ-R demonstrated good construct validity and adequate internal consistency (α's 58 - 75). Associations with age, TAQ, and Parent Symptom Diary were observed. The Treatment Burden scale demonstrated responsiveness to change. Conclusions: Parents were reliable observers of young children's symptoms and daily functioning, and PROs show promise for this age group. Research is needed to identify key symptoms in infants and young children with CF, and to develop a parent proxy PRO according to FDA/EMA guidelines.",
keywords = "Health-related quality of life, Infants, Patient reported outome, Psychometric evaluation, Treatment burden",
author = "Alpern, {Adrianne N.} and Brumback, {Lyndia C.} and Felix Ratjen and Margaret Rosenfeld and Davis, {Stephanie D.} and Quittner, {Alexandra L.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.jcf.2014.11.002",
language = "English (US)",
volume = "14",
pages = "403--411",
journal = "Journal of Cystic Fibrosis",
issn = "1569-1993",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Initial evaluation of the Parent Cystic Fibrosis Questionnaire-Revised (CFQ-R) in infants and young children

AU - Alpern, Adrianne N.

AU - Brumback, Lyndia C.

AU - Ratjen, Felix

AU - Rosenfeld, Margaret

AU - Davis, Stephanie D.

AU - Quittner, Alexandra L.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background: There is an urgent need to evaluate treatments for young children with cystic fibrosis (CF); however, efforts have been hampered by a lack of reliable, practical endpoints. To examine whether a patient-reported outcome could be reliable in children 4 to 60. months of age, we assessed the psychometric properties of the modified Parent Cystic Fibrosis Questionnaire-Revised (CFQ-R) using data from the Infant Study of Inhaled Saline (ISIS). We also characterized patterns of symptom presentation and daily functioning in children in this age range to inform future measure development. Methods: Parents ( N = 314) completed the CFQ-R and Treatment Adherence Questionnaire (TAQ) at five quarterly visits, as well as a weekly Parent Symptom Diary. Results: The Parent CFQ-R demonstrated good construct validity and adequate internal consistency (α's 58 - 75). Associations with age, TAQ, and Parent Symptom Diary were observed. The Treatment Burden scale demonstrated responsiveness to change. Conclusions: Parents were reliable observers of young children's symptoms and daily functioning, and PROs show promise for this age group. Research is needed to identify key symptoms in infants and young children with CF, and to develop a parent proxy PRO according to FDA/EMA guidelines.

AB - Background: There is an urgent need to evaluate treatments for young children with cystic fibrosis (CF); however, efforts have been hampered by a lack of reliable, practical endpoints. To examine whether a patient-reported outcome could be reliable in children 4 to 60. months of age, we assessed the psychometric properties of the modified Parent Cystic Fibrosis Questionnaire-Revised (CFQ-R) using data from the Infant Study of Inhaled Saline (ISIS). We also characterized patterns of symptom presentation and daily functioning in children in this age range to inform future measure development. Methods: Parents ( N = 314) completed the CFQ-R and Treatment Adherence Questionnaire (TAQ) at five quarterly visits, as well as a weekly Parent Symptom Diary. Results: The Parent CFQ-R demonstrated good construct validity and adequate internal consistency (α's 58 - 75). Associations with age, TAQ, and Parent Symptom Diary were observed. The Treatment Burden scale demonstrated responsiveness to change. Conclusions: Parents were reliable observers of young children's symptoms and daily functioning, and PROs show promise for this age group. Research is needed to identify key symptoms in infants and young children with CF, and to develop a parent proxy PRO according to FDA/EMA guidelines.

KW - Health-related quality of life

KW - Infants

KW - Patient reported outome

KW - Psychometric evaluation

KW - Treatment burden

UR - http://www.scopus.com/inward/record.url?scp=84937435578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937435578&partnerID=8YFLogxK

U2 - 10.1016/j.jcf.2014.11.002

DO - 10.1016/j.jcf.2014.11.002

M3 - Article

C2 - 25443473

AN - SCOPUS:84937435578

VL - 14

SP - 403

EP - 411

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

SN - 1569-1993

IS - 3

ER -